Canada Life’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Canada Life's PTGX Position: Q3 2026 in Review
Canada Life increased its Protagonist Therapeutics (PTGX) stake by 7.4% in Q3 2026, buying an estimated $508K and bringing the position to 51,612 shares worth $7.26M. The position accounts for 0.01% of the portfolio, ranked #596.
Canada Life first reported a position in PTGX in Q4 2020 and has held it in 24 quarters since. 376 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Canada Life held 51,612 shares of Protagonist Therapeutics worth $7.26M as of Q3 2026.
- Canada Life bought 3,567 Protagonist Therapeutics shares in Q3 2026, an estimated $508K.
- Protagonist Therapeutics made up 0.01% of Canada Life's portfolio in Q3 2026, its #596 holding.
- Canada Life first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 24 quarters since.
- 376 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Canada Life's 13F filing for Q3 2026, filed 13 Nov 2026.